Clinical Trial: A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX18 vs. OPDIVO(R) in Multiple Resected Solid Tumors

U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT07518043) titled 'A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX18 vs. OPDIVO(R) in Multiple Resected Solid Tumors' on April 01.

Brief Summary: This is a multicenter, randomized, double-blind, parallel-controlled phase I clinical study to evaluate the similarity in PK profile, efficacy, safety and immunogenicity of HLX18 and OPDIVO(R) in patients with resected esophageal or gastroesophageal junction cancer (EC/GEJC), melanoma (MEL), or urothelial carcinoma (UC).

Study Start Date: June 30

Study Type: INTERVENTIONAL

Condition: Esophageal and/or Cardia Cancer Melanoma Urothelial Carcinoma (UC)

Interv...